Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions
1 other identifier
expanded_access
N/A
1 country
1
Brief Summary
Expanded access to entrectinib will be given to patients with cancers harboring NTRK1/2/3, ROS1, or ALK gene fusions who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for entrectinib.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 23, 2017
CompletedFirst Posted
Study publicly available on registry
February 28, 2017
CompletedApril 26, 2019
April 1, 2019
February 23, 2017
April 24, 2019
Conditions
Interventions
Eligibility Criteria
You may qualify if:
- Diagnosis of advanced cancer with an NTRK1, NTRK2, NTRK3, ROS1, or ALK gene fusion
- Unable to participate in an ongoing entrectinib (RXDX-101) clinical trial
- Willing and able to provide written, signed informed consent
- Medically suitable for treatment with entrectinib (RXDX-101)
You may not qualify if:
- Currently enrolled in an ongoing clinical study with any other investigational agent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
1-844-Startrk (782-7875)
San Diego, California, 92121, United States
MeSH Terms
Interventions
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 23, 2017
First Posted
February 28, 2017
Last Updated
April 26, 2019
Record last verified: 2019-04